D.E. Shaw & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $56.4M | Buy |
298,090
+98,788
| +50% | +$17.3M | 0.03% | 607 |
|
|
2025
Q4 | $33.9M | Buy |
199,302
+74,936
| +60% | +$11.5M | 0.02% | 921 |
|
|
2025
Q3 | $16.4M | Buy |
124,366
+120,460
| +3,084% | +$14.4M | 0.01% | 1322 |
|
|
2025
Q2 | $415K | Sell |
3,906
-62,285
| -94% | -$6.77M | ﹤0.01% | 3719 |
|
|
2025
Q1 | $8.22M | Sell |
66,191
-235,918
| -78% | -$30.8M | 0.01% | 1538 |
|
|
2024
Q4 | $37.2M | Buy |
302,109
+43,710
| +17% | +$5.15M | 0.03% | 698 |
|
|
2024
Q3 | $28.8M | Buy |
258,399
+2,528
| +1% | +$277K | 0.02% | 785 |
|
|
2024
Q2 | $27.3M | Buy |
255,871
+48,270
| +23% | +$5.31M | 0.03% | 729 |
|
|
2024
Q1 | $25M | Sell |
207,601
-46,194
| -18% | -$5.66M | 0.02% | 806 |
|
|
2023
Q4 | $31.2M | Buy |
253,795
+25,462
| +11% | +$3.18M | 0.03% | 669 |
|
|
2023
Q3 | $29.6M | Sell |
228,333
-41,387
| -15% | -$5.51M | 0.03% | 648 |
|
|
2023
Q2 | $33.4M | Buy |
269,720
+132,137
| +96% | +$17.8M | 0.03% | 598 |
|
|
2023
Q1 | $20.1M | Buy |
137,583
+42,247
| +44% | +$6.25M | 0.02% | 893 |
|
|
2022
Q4 | $15.2M | Buy |
+95,336
| New | +$14M | 0.02% | 1105 |
|
|
2022
Q1 | – | Sell |
-6,068
| Closed | -$881K | – | 5741 |
|
|
2021
Q4 | $773K | Buy |
6,068
+414
| +7% | +$54.4K | ﹤0.01% | 4124 |
|
|
2021
Q3 | $736K | Sell |
5,654
-12,374
| -69% | -$1.87M | ﹤0.01% | 3830 |
|
|
2021
Q2 | $3.2M | Buy |
18,028
+1,334
| +8% | +$231K | ﹤0.01% | 2450 |
|
|
2021
Q1 | $2.74M | Buy |
16,694
+3,909
| +31% | +$643K | ﹤0.01% | 2314 |
|
|
2020
Q4 | $2.11M | Sell |
12,785
-2,062
| -14% | -$307K | ﹤0.01% | 2518 |
|
|
2020
Q3 | $2.12M | Sell |
14,847
-38,929
| -72% | -$4.83M | ﹤0.01% | 2359 |
|
|
2020
Q2 | $5.93M | Sell |
53,776
-21,061
| -28% | -$2.33M | 0.01% | 1534 |
|
|
2020
Q1 | $7.46M | Sell |
74,837
-255,266
| -77% | -$33M | 0.01% | 1171 |
|
|
2019
Q4 | $49.3M | Buy |
330,103
+109,891
| +50% | +$15M | 0.06% | 393 |
|
|
2019
Q3 | $28.2M | Buy |
220,212
+201,832
| +1,098% | +$27.1M | 0.03% | 612 |
|
|
2019
Q2 | $2.62M | Sell |
18,380
-73,446
| -80% | -$9.87M | ﹤0.01% | 2046 |
|
|
2019
Q1 | $13.1M | Sell |
91,826
-69,889
| -43% | -$9.12M | 0.02% | 941 |
|
|
2018
Q4 | $20M | Buy |
161,715
+63,100
| +64% | +$9.36M | 0.03% | 713 |
|
|
2018
Q3 | $16.6M | Buy |
98,615
+67,127
| +213% | +$11.5M | 0.02% | 862 |
|
|
2018
Q2 | $5.42M | Sell |
31,488
-72,726
| -70% | -$11.9M | 0.01% | 1478 |
|
|
2018
Q1 | $15.7M | Sell |
104,214
-71,302
| -41% | -$10.5M | 0.02% | 771 |
|
|
2017
Q4 | $23.6M | Buy |
175,516
+136,557
| +351% | +$18.9M | 0.03% | 610 |
|
|
2017
Q3 | $5.7M | Buy |
+38,959
| New | +$5.89M | 0.01% | 1272 |
|
|
2017
Q2 | – | Sell |
-109,652
| Closed | -$16.8M | – | 3447 |
|
|
2017
Q1 | $15.9M | Sell |
109,652
-146,213
| -57% | -$19M | 0.03% | 684 |
|
|
2016
Q4 | $27.9M | Buy |
+255,865
| New | +$28.5M | 0.05% | 494 |
|
|
2016
Q3 | – | Sell |
-106,025
| Closed | -$14.3M | – | 3442 |
|
|
2016
Q2 | $15M | Buy |
+106,025
| New | +$15.6M | 0.03% | 661 |
|
|
2016
Q1 | – | Sell |
-3,979
| Closed | -$495K | – | 3598 |
|
|
2015
Q4 | $559K | Sell |
3,979
-14,997
| -79% | -$2.08M | ﹤0.01% | 3022 |
|
|
2015
Q3 | $2.52M | Buy |
18,976
+4,365
| +30% | +$752K | ﹤0.01% | 1923 |
|
|
2015
Q2 | $2.57M | Buy |
+14,611
| New | +$2.62M | ﹤0.01% | 1992 |
|
|
2013
Q4 | – | Sell |
-175,398
| Closed | -$16.1M | – | 4569 |
|
|
2013
Q3 | $16.1M | Sell |
175,398
-290,859
| -62% | -$23.5M | 0.03% | 693 |
|
|
2013
Q2 | $32M | Buy |
+466,257
| New | +$28.5M | 0.06% | 353 |
|
Other funds holding JAZZ
VPM
VCM
EC
D.E. Shaw & Co's JAZZ Position: Q1 2026 in Review
D.E. Shaw & Co increased its Jazz Pharmaceuticals (JAZZ) stake by 50% in Q1 2026, buying an estimated $17.3M and bringing the position to 298,090 shares worth $56.4M. The position accounts for 0.03% of the portfolio, ranked #607.
D.E. Shaw & Co first reported a position in JAZZ in Q2 2013 and has held it in 40 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- D.E. Shaw & Co held 298,090 shares of Jazz Pharmaceuticals worth $56.4M as of Q1 2026.
- D.E. Shaw & Co bought 98,788 Jazz Pharmaceuticals shares in Q1 2026, an estimated $17.3M.
- Jazz Pharmaceuticals made up 0.03% of D.E. Shaw & Co's portfolio in Q1 2026, its #607 holding.
- D.E. Shaw & Co first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.